Laboratory Medicine Consultants LTD
Laboratory Medicine Consultants LTD was paid $9.16M by Medicaid between Jan 2018 and Dec 2024, across 162 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 17% of everything it billed.
LAS VEGAS, NV 89128
Next to other Clinical Medical Laboratory providers in Nevada
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 26,612 | $215K | |
| 2019 | 179,742 | $1.08M | |
| 2020 | 190,091 | $1.33M | |
| 2021 | 238,813 | $1.86M | |
| 2022 | 171,096 | $1.65M | |
| 2023 | 184,348 | $1.75M | |
| 2024incomplete | 207,988 | $1.27M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 17% | 57,140 | 49,077 | $1.54M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 8.8% | 22,962 | 19,163 | $803K |
| 85027 | 5.9% | 148,174 | 78,117 | $537K | |
| 80053 | Comprehensive metabolic panel | 5.4% | 85,206 | 56,991 | $493K |
| 87150 | 4.2% | 953 | 873 | $389K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 3.0% | 28,459 | 24,520 | $271K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 3.0% | 28,393 | 24,465 | $270K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.8% | 8,911 | 6,766 | $259K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.7% | 57,580 | 33,029 | $250K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2.2% | 17,870 | 16,030 | $199K |
| 83605 | 2.1% | 19,604 | 11,540 | $196K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 2.1% | 23,881 | 21,231 | $190K |
150 more codes
| 87481 | 2.0% | 8,352 | $179K | |
| 88312 | 1.8% | 11,551 | $166K | |
| 88307 | 1.6% | 1,743 | $150K | |
| 84484 | 1.6% | 22,074 | $146K | |
| 83735 | 1.5% | 36,597 | $138K | |
| 83880 | 1.5% | 7,482 | $133K | |
| 87660 | 1.4% | 25,333 | $133K | |
| 81513 | 1.4% | 4,514 | $125K | |
| 84703 | 1.4% | 28,593 | $124K | |
| 82330 | 1.3% | 7,485 | $115K | |
| 83690 | 1.2% | 27,816 | $110K | |
| 85730 | 1.1% | 26,645 | $102K | |
| 80076 | <1% | 18,906 | $82K | |
| 85610 | <1% | 31,945 | $73K | |
| 80069 | <1% | 16,639 | $68K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,279 | $66K |
| 87581 | <1% | 3,425 | $64K | |
| 84702 | <1% | 7,832 | $63K | |
| 81001 | <1% | 38,273 | $61K | |
| 88173 | <1% | 1,871 | $60K | |
| 86850 | <1% | 14,204 | $60K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,687 | $57K |
| 87486 | <1% | 3,279 | $56K | |
| 87653 | <1% | 6,937 | $55K | |
| 84100 | <1% | 22,142 | $55K | |
| 88304 | <1% | 3,932 | $53K | |
| 82550 | <1% | 13,967 | $53K | |
| 88342 | <1% | 2,784 | $49K | |
| 84132 | <1% | 10,380 | $46K | |
| 81025 | <1% | 11,344 | $43K | |
| 80047 | <1% | 7,335 | $38K | |
| 86140 | <1% | 13,494 | $37K | |
| 86901 | <1% | 20,419 | $34K | |
| 85379 | <1% | 4,881 | $33K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,682 | $33K |
| 80202 | <1% | 4,558 | $31K | |
| 86900 | <1% | 18,947 | $31K | |
| 87077 | <1% | 6,313 | $30K | |
| 82947 | <1% | 5,630 | $28K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,936 | $28K |
| 88142 | <1% | 4,072 | $28K | |
| 88141 | <1% | 3,592 | $28K | |
| 87040 | <1% | 2,729 | $26K | |
| 87529 | <1% | 1,296 | $26K | |
| 80074 | <1% | 1,062 | $25K | |
| 80061 | Lipid panel | <1% | 3,710 | $25K |
| 85007 | <1% | 14,126 | $25K | |
| 82247 | <1% | 10,722 | $25K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,117 | $24K |
| 87480 | <1% | 6,774 | $24K | |
| 87510 | <1% | 6,776 | $24K | |
| 85018 | <1% | 8,387 | $22K | |
| 85384 | <1% | 3,585 | $21K | |
| 87511 | <1% | 2,138 | $20K | |
| 81003 | <1% | 18,444 | $20K | |
| 82248 | <1% | 7,269 | $20K | |
| 87563 | <1% | 1,714 | $19K | |
| 86923 | <1% | 724 | $18K | |
| 82140 | <1% | 2,136 | $17K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,710 | $16K |
| 88341 | <1% | 1,150 | $14K | |
| 84112 | <1% | 690 | $13K | |
| 88360 | <1% | 191 | $13K | |
| 86920 | <1% | 391 | $12K | |
| 85049 | <1% | 4,024 | $12K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,349 | $12K |
| 84439 | <1% | 2,559 | $12K | |
| 82077 | <1% | 1,782 | $10K | |
| 86880 | <1% | 3,503 | $10K | |
| 87640 | <1% | 853 | $10K | |
| 87430 | <1% | 1,548 | $10K | |
| 88356 | <1% | 59 | $10K | |
| 80055 | <1% | 321 | $9K | |
| 82728 | <1% | 1,142 | $8K | |
| 87625 | <1% | 1,263 | $7K | |
| 82962 | <1% | 2,726 | $7K | |
| 84145 | <1% | 721 | $7K | |
| 88185 | <1% | 67 | $6K | |
| 88112 | <1% | 1,077 | $6K | |
| 84295 | <1% | 5,690 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 934 | $6K |
| 85014 | <1% | 3,353 | $5K | |
| 85045 | <1% | 2,408 | $5K | |
| 88720 | <1% | 1,835 | $5K | |
| 86780 | <1% | 612 | $5K | |
| 87088 | <1% | 1,534 | $5K | |
| 82435 | <1% | 4,865 | $4K | |
| 88313 | <1% | 308 | $4K | |
| 82607 | <1% | 449 | $4K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 226 | $4K |
| 83550 | <1% | 973 | $3K | |
| 85651 | <1% | 1,773 | $3K | |
| 82570 | <1% | 1,632 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 834 | $3K |
| 84478 | <1% | 1,038 | $3K | |
| 83540 | <1% | 998 | $3K | |
| 86803 | <1% | 445 | $3K | |
| 87808 | <1% | 405 | $2K | |
| 85390 | <1% | 771 | $2K | |
| 88314 | <1% | 55 | $2K | |
| 88189 | <1% | 147 | $2K | |
| 83615 | <1% | 542 | $2K | |
| 87070 | <1% | 355 | $2K | |
| 87210 | <1% | 2,005 | $2K | |
| 88302 | <1% | 133 | $1K | |
| 82565 | <1% | 884 | $1K | |
| 89051 | <1% | 502 | $1K | |
| 88363 | <1% | 279 | $1K | |
| 82746 | <1% | 140 | $1K | |
| 87205 | <1% | 331 | $1K | |
| 85652 | <1% | 733 | $970.11 | |
| 85060 | <1% | 157 | $931.84 | |
| 87186 | <1% | 224 | $926.30 | |
| 87147 | <1% | 332 | $881.51 | |
| 85576 | <1% | 17 | $791.64 | |
| 87420 | <1% | 119 | $777.10 | |
| 82010 | <1% | 148 | $754.94 | |
| 86593 | <1% | 318 | $714.00 | |
| 84550 | <1% | 238 | $618.36 | |
| 85097 | <1% | 52 | $616.12 | |
| 87340 | <1% | 162 | $606.30 | |
| 88311 | <1% | 211 | $520.09 | |
| 81002 | <1% | 306 | $519.75 | |
| 84436 | <1% | 128 | $506.24 | |
| 84155 | <1% | 947 | $496.30 | |
| 88184 | <1% | 67 | $435.26 | |
| 88300 | <1% | 143 | $416.49 | |
| 82945 | <1% | 206 | $393.64 | |
| 82533 | <1% | 30 | $303.97 | |
| 82150 | <1% | 87 | $245.38 | |
| 84300 | <1% | 105 | $234.96 | |
| 87177 | <1% | 49 | $205.66 | |
| 86705 | <1% | 38 | $112.56 | |
| 86709 | <1% | 38 | $107.52 | |
| 87075 | <1% | 27 | $96.90 | |
| 88108 | <1% | 22 | $87.89 | |
| 87102 | <1% | 12 | $68.76 | |
| 83935 | <1% | 12 | $51.15 | |
| 83930 | <1% | 14 | $45.10 | |
| 84156 | <1% | 22 | $42.50 | |
| 86308 | <1% | 13 | $35.30 | |
| 82009 | <1% | 13 | $33.88 | |
| 84520 | <1% | 90 | $29.70 | |
| 86592 | <1% | 14 | $29.10 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 0% | 297 | $0.00 |
| 80320 | 0% | 773 | $0.00 | |
| 80329 | 0% | 121 | $0.00 | |
| 87631 | 0% | 2,635 | $0.00 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 1,344 | $0.00 |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | 0% | 132 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Pathology Solutions LLC | Eatontown, NJ | $5.39M |
| Laboratory of Dermatopathology Adx, LLC | Woodbury, NY | $3.57M |
| Cascade Pathology Services, Corp | Portland, OR | $2.52M |
| Laboratory Medicine Consultants LTD | Las Vegas, NV | $2.33M |
| Consultants in Laboratory Medicine of Greater Toledo | Toledo, OH | $2.28M |
| Greensboro Pathology, LLC | Greensboro, NC | $2.16M |
| Mark and Kambour MD PA | Miami Lakes, FL | $776K |
| Dermpath New England, LLC | Boston, MA | $643K |
| Western Pathology Consultants, LTD | Reno, NV | $554K |
| Seacoast Pathology, INC. | Exeter, NH | $392K |
| Hallmark Pathology, P.C. | Melrose, MA | $118K |
| Richard Bernert, LLC | Scottsdale, AZ | $23K |
| Mid-Atlantic Pathology Services, INC. | Sterling, VA | $13K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.